Genome-based healthcare

Genome (personal genome)-based healthcare (genome diagnosis and examination) technology is a technology that predicts and diagnoses individual physical characteristics or diseases by prepping and analyzing genetic information from individual blood, saliva, and epithelial cells. Clinomics Inc.(Hereinafter, Clinomics) has 10 types of products that predict genetic-based physical characteristics or diseases, including "Geno-P", "Geno-D", and "Geno-Dx". Clinomics' genomic testing service has a variety of test service (product) groups for each disease (phenotype) and is designed to cover a wide range of areas such as cancer disease, complex disease, rare disease, nutrition, aging, and ancestor analysis. In addition, each type of test consists of prediction and pre-test, neonatal screening, carrier test, diagnostic test, and other types (nutritional test), so it has the advantage of providing customized test services to various markets and consumers in Korea and abroad.

Liquid biopsy platform

The liquid biopsy platform product is a technology that analyzes the patient's body fluids (e.g., urine, saliva, mainly blood) to detect and analyze "Circulating Tumor Cell (CTC)" or "Circulating Tumor Cell (cfDNA)" in the blood. Clinomics has a differentiated technology from other liquid biopsy companies in Korea and abroad. Other companies are focusing on either CTC or cfDNA, but Clinomics has developed a fully automated CD-PRIME™ (Blood Centrifuge) called 'OPR-2000' in 2020 and can detect CTC or cfDNA at the same time. There are our related clinic products such as OPR-1000, CTC-SOLO, CTC-DUO, OPR-2000, LBx1 and LBx2.

Cancer Diagnosis/Monitoring

Cancer diagnosis/monitoring products provide information for cancer treatment or prescription by analyzing the mutation status of cancer-causing genes (multi-gene) in tissues or blood of cancer patients, and continuously monitoring the mutation status after the treatment. Clinomics' current cancer diagnosis/monitoring products include Cancer-PRIME™, Liver Cancer Panel, and Maternal Cancer Panel. Clinomics developed a gene analysis panel that can diagnose and monitor lung/liver/gynecological cancer and solid cancer by analyzing cfDNA and CTC obtained from patients' blood as well as target cancer-related genes based on genetic diagnostic panel manufacturing technology, and is currently undergoing clinical and performance verification. The Companion Diagnosis is that even if the same anticancer drug is administered, some patients completely defeat cancer, and other patients have no effect or resistance, which is due to individual differences in the patient's genetic characteristics and variation. In other words, Companion diagnosis (CDx) means diagnosing these individual genetic characteristics and mutations and selecting a drug. Companion diagnosis is the basis of personalized medical care, such as increasing the response rate of drugs, minimizing side effects, improving the quality of life for patients, reducing unnecessary prescriptions, and contributing to the health of insurance finances. Clinomics is conducting a variety of companion diagnostic services, including specific and sensitive detection of ROS1 gene fusion of non-small cell lung cancer through related know-how, tools, and its products, NSCLC. The services currently available include ROS1 (non-small cell lung cancer), PIK3CA (breast cancer), and KRAS (lung/colon cancer).

Early diagnosis based on multiple omics

Multi-omics-based early diagnosis products predict (or early diagnosis) the possibility of disease by synthesizing information such as individual genome information from blood, as well as information such as epigenome, proteomics, expressionics, and metabolism. Clinomics is currently developing early diagnosis products for diseases such as suicide/depression, heart/myocardiology, and early diagnosis products for cancer include colorectal cancer, lung cancer, and stomach cancer. Early diagnosis of cancer (lung/stomach cancer, and colon cancer) requires epigenome analysis(or exogenous analysis) to overcome the limitations of previously well-known single nucleotide polymorphism (SNP) and somatic mutation-based research results, and to enable accurate diagnosis prediction according to the characteristics of various carcinomas. The above multi-omics data analysis is useful for identifying cancer influences and correlations between omics' and omics by types and enables the discovery of the most accurate biomarkers required for early cancer diagnosis. In addition, Clinomics analyzes and tests based on non-invasive liquid biopsy using blood and gastric juice, so it is possible to implement various practical technologies such as early cancer prediction and early diagnosis.

Bio BigData Center

The need for genomic/health/medical information cloud commercialization services based on high-capacity computing hardware is becoming stronger to standardize, analyze, process, and store exploding bio&medical data. High-speed transmission technology for fast transmission of tens/hundreds of terabytes or more of genomic data to domestic/external networks and services that efficiently handle (manage) complex programs and DBs are essential in the BigData field. With the advent of the convergence era, the need for integrated BigData analysis and data distribution of bio/health information, and medical information is increasing, and Clinomics is responding quickly to this trend by establishing its own BBC(Abbreviation of Bio BigData Center).